** Shares of Roivant Sciences gain 2.5% to $12.35 premarket
** Healthcare company Organon says it has agreed to buy skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion
** The deal gives OGN access to Dermavant's psoriasis cream, VTAMA, approved by the U.S. FDA in May 2022
** OGN to make an upfront payment of $175 million, as well as milestone payments of up to $950 million as part of the deal
** OGN expects to close the transaction in Q4 this year
** Up to last close, ROIV shares up 7.3% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.